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The role of daily physical activity and nutritional status 
on bone turnover in cystic fibrosis:  
a cross-sectional study
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ABSTRACT | Background: Nutritional status and daily physical activity (PA)  may be an excellent tool for the maintenance 
of bone health in patients with cystic fibrosis (CF).  Objective: To evaluate the relationship between nutritional status, 
daily physical activity and bone turnover in cystic fibrosis patients. Method: A cross-sectional study of adolescent and 
adult patients diagnosed with clinically stable cystic fibrosis was conducted. Total body, femoral neck, and lumbar spine 
bone mineral density (BMD) were determined by dual energy X-ray absorptiometry and bone metabolism markers ALP, 
P1NP, PICP, and ß-CrossLaps. PA monitoring was assessed for 5 consecutive days using a portable device. Exercise 
capacity was also determined. Serum 25-hydroxyvitamin D and vitamin K were also determined in all participants. 
Results: Fifty patients (median age: 24.4 years; range: 16-46) were included. BMI had positive correlation with all BMD 
parameters, with Spearman’s coefficients ranging from 0.31 to 0.47. Total hip bone mineral density and femoral neck 
BMD had positive correlation with the daily time spent on moderate PA (>4.8 metabolic equivalent-minutes/day; r=0.74, 
p<0.001 and r=0.72 p<0.001 respectively), daily time spent on vigorous PA (>7.2 metabolic equivalent-minutes/day; r=0.45 
p<0.001), body mass index (r=0.44, p=0.001), and muscle mass in limbs (r=0.41, p=0.004). Levels of carboxy-terminal 
propeptide of type 1 collagen were positively associated with the daily time spent on moderate (r=0.33 p=0.023) and 
vigorous PA (r=0.53, p<0.001). Conclusions: BMI and the daily time spent on moderate PA were found to be correlated 
with femoral neck BMD in CF patients. The association between daily PA and biochemical markers of bone formation 
suggests that the level of daily PA may be linked to bone health in this patient group. Further research is needed to 
confirm these findings. 
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BULLET POINTS
• Physical therapy in cystic fibrosis patients is correlated with bone health.
• Bone health can improve with physical activity.
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Introduction
Thanks to advances in the treatment and care of 
patients with cystic fibrosis (CF), the life expectancy1 of 
these patients has increased. However, this fact has not 
resulted in quality of life because different comorbidities 
have been observed in adulthood. Disturbances in bone 
metabolism, particularly significant reductions in bone 
mineral density (BMD), are recognized as additional 
and serious complications in these CF patients, with 
prevalence ranging from 40% to 70%2,3. The low 
BMD found in these patients is multifactorial and 
many factors have been suggested as explanation4-10. 
One of these explanations is based on intestinal 
malabsorption, with vitamin D deficiency caused by 
exocrine pancreatic insufficiency4. Evidence suggests 
that the absorption of vitamins D and K may not be 
sufficient to ensure proper skeletal mineralization in 
CF adolescents5. Another bone metabolic disorder 
found in CF patients is imbalance in bone turnover, 
with decreased bone formation as the predominant 
change and increased bone resorption in infective 
exacerbation or severe lung disease6-8. Moreover, 
severe lung disease also affects bone mass. Forced 
expiratory volume in one second (FEV
1
) expressed as 
the percentage of the predicted value is a robust marker 
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for lung disease and helps to explain the variability of 
BMD9. This correlation is explained in part because 
severe lung disease adversely affects exercise capacity. 
When monitoring daily physical activity (PA), it 
was noted that the most active patients have greatest 
bone mass, confirmed by exercise capacity test10. 
Nevertheless, there is no confirmation of whether 
bone turnover has a relationship with PA and its 
intensity or with nutritional status. This study was 
designed to evaluate the relationship between daily 
level of PA, nutritional status, and bone parameters 
(BMD and biomarkers of bone turnover) in a sample 
of adolescents and adults with CF.
Method
Participants and study design
We conducted a cross-sectional study that included 
patients over 16 years of age diagnosed with CF and 
attending our Cystic Fibrosis Unit. All participants 
exhibited high sweat chloride levels (>60 mmol/L), 
had characteristic clinical features of CF, and their 
diagnoses were confirmed by repeated genetic analysis. 
Patients who had undergone lung transplantation and/or 
had a recent acute exacerbation requiring treatment 
with antibiotics (within 6 weeks prior to the study) 
were excluded. The Ethics Committee of the Virgen 
del Rocío Hospital, Sevilla, Spain approved this study 
(approval number 14/2008) and written informed 
consent was obtained from all participants.
Maximal cardiopulmonary exercise testing
In order to evaluate the tolerance to exercise, maximal 
cardiopulmonary exercise testing was performed with 
a MasterScreen CPX cycle ergometer model Via Sprint 
150 (ViaSys Healthcare, Hoechberg, Germany), as 
previously described10 and according to the international 
standard11. The test is a symptom-limited exercise 
and involves measurements of respiratory oxygen 
uptake (VO2), carbon dioxide production (VCO2), 
and ventilatory measures. It was performed with 
electrocardiographic, heart rate, and pulse oximetry 
monitoring. All measurements were integrated into the 
cycle ergometer device and evaluated simultaneously 
during the test. On completion of the exercise test, 
heart rate, blood pressure, leg fatigue, chest pain, and 
dyspnea were assessed using the modified Borg scale.
Physical activity monitoring
Physical activity was measured in all participants 
on five consecutive days using a portable physical 
activity and lifestyle monitor (SenseWear Armband, 
BodyMedia Inc., Pittsburgh, PA, USA), which estimates 
a person’s rest and exercise energy expenditure. 
The accelerometer was positioned on the right brachial 
triceps and was only removed for showering12. 
The records were considered valid if the mean wearing 
time was ≥600 min/day in the 5-day period and at least 
one of the five days landed on a weekend. The use of 
this device has been validated against doubly labeled 
water13. The time (in minutes) spent with an energy 
expenditure of >3 metabolic equivalent-minutes/day 
(METs) was considered “mild” activity, time spent at 
>4.8 METs was considered “moderate” activity, and 
when energy expenditure was of >7.2 METs, it was 
considered “vigorous” activity, as suggested by the 
U.S. Department of Health and Human Services14. 
The average number of daily steps at each intensity 
level was calculated in all participants.
Nutritional assessment
The values for lean muscle mass and fat mass 
were assessed in the extremities by dual energy X-ray 
absorptiometry15 (DXA). Body mass index, serum 
albumin, and serum levels of vitamins D and K were 
determined in all participants. For biochemical assays, 
blood samples were drawn in the morning after an 
overnight fast. Concentrations of 25-hydroxyvitamin D 
(25OHD) were determined by high-performance liquid 
chromatography (HPLC) on an Agilent 1100 HPLC 
system (Agilent Technologies Inc., Santa Clara, 
CA, USA). Plasma vitamin K concentrations were 
assessed by means of HPLC.
Bone mineral density and bone turnover 
biomarkers
Total body, femoral neck, and lumbar spine 
(L1-L4) BMD were determined by dual-energy 
X-ray absorptiometry (Hologic QDR X-ray 4500W 
Bone Densitometer). DXA results were expressed in 
absolute BMD units (grams per square centimeter), 
T-scores, and Z-scores. The T-score was defined as 
the number of standard deviations above or below the 
mean for a healthy 20-year-old adult of the same sex 
and ethnicity as the patient. The Z-score was defined 
as the number of standard deviations a patient’s BMD 
differs from the average BMD of their age, sex, and 
ethnicity16.
Serum levels of β-CrossLaps and amino-terminal 
propeptide of type 1 collagen (P1NP) were measured 
using an electrochemiluminescence method on a Cobas 
e411 analyzer (Roche Diagnostics, Indianapolis, IN, 
USA). Bone-specific alkaline phosphatase (ALP) and 
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serum levels of carboxy-terminal propeptide of type 1 
collagen (P1CP) were assayed using ELISA (Quidel 
Corporation, San Diego, CA, USA) on an automated 
TRITURUS processor (Grifols International S.A., 
Barcelona, Spain).
Statistical analysis
The simple size calculation was estimated using 
the Dixon and Mansey formula17. This sample size 
was calculated using a power of 80% and a type I 
error of 5%.
Continuous data were expressed as medians and 
interquartile ranges (Q3- Q1) and categorical data were 
expressed with relative frequencies. We performed 
a Mann-Whitney U test and Chi-Square test for 
comparisons between sex groups. The associations 
between functional and structural parameters were tested 
using the non-parametric Rho Spearman correlation. 
Spearman’s rank correlation can be interpreted in 
terms of the amount of mutual information between 
two variables. An observed value of ρ is significantly 
different from zero (r will always maintain −1≤r≤1). 
We calculated the probability that it would be greater 
than or equal to the observed r, given the null hypothesis, 
by using a permutation test. An advantage of this 
approach is that it automatically takes into account 
the number of tied data values in the sample and the 
way they are treated in computing the rank correlation. 
All tests were performed using 0.2 and 0.05 as the 
probability of a Type II error and probability of a 
Type I error, respectively.
All statistical calculations were performed using 
the SPSS 16.0 statistical software package (SPSS 
Inc., Chicago, IL, USA). Two-tailed p<0.05 were 
considered statistically significant.
Results
We included 50 patients in our sample (23 males 
and 27 females) with a median age 24.4 (interquartile 
range - IQR=5.8) years. A total of 48 patients (96%) 
were undergoing oral corticosteroid treatment. 
Two of the patients (4%) had been diagnosed with 
allergic bronchopulmonary aspergillosis (ABPA) and 
were being treated intermittently with prednisone 
(10 mg/day per os) for the last three years, and 
23 patients (96%) had also been receiving inhaled 
corticosteroids (budesonide) at doses of 200-400 μg 
administered twice a day. All patients were prescribed 
vitamin supplementation (Vitamin A 1.50 mg, Vitamin 
D 0.01 mg, and Vitamin E 200 mg). There was no 
documented secondary hepatopathy in any patient.
The male patients showed more wattage, 130 vs 100 
(p=0.001) and spent more time on a moderate activity 
24 vs 11.6 (p=0.045). There was no difference in the 
remaining parameters between sex groups. The general 
characteristics of the study participants are shown 
in Table 1.
Nutritional status, bone mineral density, and 
markers
Body mass index (BMI) showed a positive correlation 
with all of the BMD parameters, with Spearman’s 
coefficient ranging from 0.31 to 0.47. Muscle mass 
had a positive relationsip with all markers ranging 
from 0.48 to 0.43 for bone formation markers and 
0.33 for serum levels of β-CrossLaps. In contrast, 
the percentage of fat mass had a negative correlation 
with the formation and resorption markers, ranging 
from –0.57 to –0.34. A positive correlation was found 
between 25-hydroxyvitamin D and whole-body 
Z-scores (r=0.34, p=0.03).
Daily physical activity, bone mineral density, 
and markers
Wattage showed a positive correlation with all 
BMD parameters. Spearman’s coefficient, ranging 
from 0.30 to 0.49, also showed a weak positive 
correlation with ALP (r=0.29 p=0.04).
All variables of daily physical activity (PA) had a 
positive correlation with at least two BMD parameters. 
The strongest correlation was found between the 
average number of minutes spent on moderate daily 
PA (>4.8 METs) and hip BMD (r=0.74 p<0.001) 
(Table 2). Remodeling markers only had a positive 
correlation with moderate and vigorous daily PA with 
a higher coefficient in vigorous activity and formation 
markers. The relationship of bone formation markers 
with 4.8 METs and 7.2 METs is presented in Figure 1.
Discussion
The foundations for lifetime bone health are 
established from infancy to adolescence and require 
adequate nutrition, body mass, PA, and hormone 
production18. CF compromises the gains during 
puberty when growth and mineral accrual are most 
rapid19. The values of BMD found in our CF patients 
are consistent with previous findings2. Our results 
show that patients diagnosed with CF with high levels 
of daily PA have higher BMD values and increased 
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Table 1. General characteristics of patients with cystic fibrosis stratified according to sex.
Total Cohort (N=50) Males (n=23) Females (n=27) p
Demographic data
Age years (IQR) 24.5 (19-28) 25 (19-30) 24 (20-27) 0.59
Corticosteroids 48 (96) 22 (95.6) 26 (96.3) 1.00
BMI Kg/m2 (IQR) 20.5 (18.8-21.9) 20.6 (18.9-22.8) 19.9 (18.7-21.6) 0.30
ΔF508 mutation 33 (66.0) 16 (69.6) 17 (63.0) 0.62
ΔF508 homocigosis 15 (30.0) 8 (34.8) 7 (25.9) 0.50
ΔF508 heterocigosis 18 (36.0) 8 (34.8) 10 (37.0) 0.87
R334W mutation 10 (20.0) 6 (26.1) 4 (14.8) 0.32
Exocrine pancreatic insufficiency 36 (72.0) 15 (65.2) 21 (77.8) 0.32
Exercise tolerance
FEV1% predicted (IQR) 60.3 (35.2-80.9) 47.4 (35.2-80.8) 60.7 (32.6-82.6) 1.00
FVC % predicted (IQR) 78.0 (59.3-95.3) 77 (59.3-93.5) 78.6 (58.1-99.9) 0.90
VO2max% (IQR) 66.5 (58.0-81.5) 65 (58-75) 72 (60.9-89.0) 0.22
Wmax (IQR) 110 (80-130) 130 (110-150) 100 (80-110) 0.001
6MWT distance meters (IQR) 640 (582-679) 647 (620-695) 615 (562-675) 0.05
Daily physical activity
Device wearing min/day (IQR) 618 (598-637) 614 (598-643) 622 (589-634) 0.63
PA >3 METs min/day (IQR) 152 (107-231) 154 (117-239) 121 (97-230) 0.37
PA >4.8 METs min/day (IQR) 11.6 (5.5-35.4) 24 (6.25-56.55) 10.2 (3.5-16.6) 0.04
PA >7.2METs min/day (IQR) 0.5 (0-2.2) 0.75 (0.25-2.0) 0.16 (0-1.12) 0.05
Steps/day (IQR) 8,361 (5,662-10,322) 8,859 (5,676-12,472) 7,972 (5,294-9,660) 0.22
Osteoporosis
Z score <1 SD (%) 25 (51.0) 12 (52.2) 13 (48.1) 0.45
Z score <2 SD (%) 2 (4) 2 (8.7) 0 (0) 0.22
IQR: interquartile range; BMI: body mass index; FEV
1
: forced expiratory volume in one second; FVC: forced vital capacity; VO2max% theoretical: 
maximal oxygen consumption; Wmax (watts): maximal power output; PA: physical activity; METs: metabolic equivalents (minutes/day). 
Data given as median (IQR).
Figure 1. Correlation beetween bone formation markers and daily physical activity. (A) PA>4.8 METs min/day versus P1NP ng/mL, 
r=0.35 p=0.013; (B) PA>7.2 METs min/day versus P1NP ng/mL, r=0.42 p=0.003; (C) PA>4.8 METs min/day versus PICP ng/mL, r=0.32 
p=0.023; (D) PA>7.2 METs min/day versus PICP ng/mL, r=0.53 p<0.001.
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serum levels of bone formation markers. The bone 
remodeling markers in our sample were significantly 
different from the reference values of the normal 
adult population.
Routine screening for reduced BMD using 
dual energy X-ray absorptiometry (DXA) scans is 
recommended as detailed in published guidelines2,20. 
The recommendation is for this procedure to be 
performed every 5 years, 2 years, or 1 year, depending 
on Z-score values in young adults. Bone loss has been 
observed in several longitudinal studies in young 
adults with CF21,22 reporting annualized losses in BMD 
of 0.5 to 2.1%. This significant loss requires a more 
thorough investigation. The positive correlation found 
between BMI and the BMD values was in agreement 
with several previous studies9,23 and suggests that 
improving vigilance in the periods between DXA 
scans could result in an alternative marker.
Concerning vitamins, the normal rate of 25OHD 
in these patients was 20-40 ng/mL. We only found 
a weak positive relationship between 25OHD and 
BMD values, although all patients had vitamin D 
supplementation. Recent meta-analyses show that 
vitamin D supplementation increases the levels of 
vitamin D in the blood but does not improve BMD 
values24. This suggests that recommended vitamin 
Table 2. Spearman’s correlations of exercise tolerance parameters, daily physical activity, and nutritional parameters with bone mineral 
density and bone turnover biomarkers in adult CF patients.
BMD r p Bone TurnoverBiomarkers r p
EXERCISE TOLERANCE AND DAILY PHYSICAL ACTIVITY PARAMETERS

































































































































































































BMD: bone mineral density; METs: metabolic equivalents (minutes/day); P1NP: amino-terminal propeptide of type 1 collagen; P1CP: carboxy-
terminal propeptide of type 1 collagen; ALP: bone-specific alkaline phosphatase; BMI: body mass index; 25OHD: 25-hydroxyvitamin D.
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supplementation is useful but insufficient for the 
maintenance of bone health in these patients2.
PA and exercise training play an important role 
in the clinical management of patients with cystic 
fibrosis (CF). Exercise training is more common 
and recognized as an essential part of rehabilitation 
programs and overall CF care2,20. However, exercise 
remains underutilized and not always incorporated 
into the CF management routine.
Our results suggest that there is no correlation of 
turnover markers in PA with low intensity. However, 
when daily physical activity is moderate (>4.8 METS) 
or vigorous (>7.2 METS), they are significantly 
correlated with circulating levels of bone formation 
markers. The present study is the first to demonstrate 
that vigorous daily PA may have a correlation with the 
rate of bone remodeling by favoring bone formation in 
adolescent and young adult CF patients. These findings 
suggest that the intensity of the exercise can have 
an influence on the bone turnover of CF patients 
and therefore should be controlled in the exercise 
prescriptions to improve bone health.
This is suggested in a review of weight-bearing 
exercise25, which states that exercise prescriptions 
should generate bone strains that are not only of 
a sufficiently high magnitude, but also unusually 
distributed and high rate.
Published data on the amount of time spent on 
PA among patients with CF are limited. Although 
Troosters et al.12 have previously described the use of 
accelerometers to monitor daily PA in this population 
group, they did not focus the possible effects on BMD 
nor on bone remodeling markers. In contrast, other 
authors have established models in which a patient’s 
maximal oxygen consumption (VO2max) could be 
used as a BMD predictor26,27.
There are some limitations to the present study. 
First, results on bone turnover markers in CF patients 
should be interpreted with caution. In particular, levels 
of bone turnover markers may be altered in a specific 
subset of CF patients with impaired liver function. 
In addition, alterations in BMI, use of steroids, 
changes in lifestyle, and other variables may have 
confounded the results of bone turnover markers. 
The cross-sectional nature of our study means that the 
effect of exercise on bone metabolism was collected 
retrospectively and there was no control of vitamin 
supplementation adherence. Nevertheless, it should be 
noted that exercise is unlikely to result in short-term 
changes in bone turnover markers28. Future longitudinal 
studies with long follow-up periods are needed to 
confirm and expand our findings.
Despite these limitations, BMI and daily time 
spent on moderate physical activity were found to be 
correlated with femoral neck BMD in CF patients. 
The correlation between daily PA and biochemical 
markers of bone formation suggests that exercise is 
linked to bone health in this patient group. Further 
longitudinal studies are needed in order to confirm 
these findings.
Conclusion
BMI and daily time spent on moderate PA were 
found to be correlated with femoral neck BMD in 
CF patients. The correlation between daily PA and 
biochemical bone formation markers suggests that 
moderate and vigorous levels of PA may improve 
bone health in this population. Further research is 
needed in order to confirm these findings.
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